Kintara Therapeutics Inc (NASDAQ:KTRA) (FRA:3DM) CEO Saiid Zarrabian tells Proactive the group has reported topline data results from the recurrent arm of its open-label, Phase 2 clinical study of its lead compound VAL-083.
Zarrabian says the Phase 2 trial testing VAL-083 in glioblastoma multiforme (GBM) patients was ‘encouraging’ as it ‘showed an ‘improvement over the standard of care.’
Story by ProactiveInvestors
Please Help Support BeforeitsNews by trying our Natural Health Products below!
Order by Phone at 888-809-8385 or online at https://mitocopper.com M - F 9am to 5pm EST
Order by Phone at 888-388-7003 or online at https://www.herbanomic.com M - F 9am to 5pm EST
Order by Phone at 888-388-7003 or online at https://www.herbanomics.com M - F 9am to 5pm EST
Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!
HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation
Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.
Oxy Powder - Natural Colon Cleanser! Cleans out toxic buildup with oxygen!
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover - Reduces Smart Meter radiation by 96%! (See Video)